The use of trimethoprim-sulfamethoxazole for serious MRSA infections

Infections in Medicine

Volumn 22, Issue 10, 2005, Pages 507-510

  Shams, Wael E ^a,b   McCormick, Malkanthie ^a   Rapp, Robert P ^a   Evans, Martin E ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b EAST TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

Bacteremia; Drug resistance; Endocarditis; Methicillin resistant Staphylococcus aureus; Trimethoprim sulfamethoxazole

Indexed keywords

COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; LINEZOLID; METICILLIN; VANCOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; CASE REPORT; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; HEART ARREST; HEART CATHETER; HEART TRANSPLANTATION; HUMAN; KIDNEY FAILURE; LUNG EDEMA; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; RESPIRATORY FAILURE; STAPHYLOCOCCUS INFECTION; TREATMENT FAILURE;

EID: 33645742251     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001;32(suppl 2):S114-S32.
2. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control. 2003;31:481-498.
3. Lodise TP Jr, McKinnon PS, Rybak MJ. Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance. Infect Control Hosp Epidemiol. 2003; 24:655-661.
4. Waldvogel F. Staphylococcus aureus. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 5th ed. New York: Churchill Livingstone Inc; 2000:2069-2089.
5. Lowy F. Staphylococcus aureus infections. N Engl J Med. 1998;339:520-532.
6. Kucers A, Crowe S, Grayson M, et al. Trimethoprim, Co-trimoxazole (Co-T), and other trimethoprim combinations. In: Kucers A, Crowe SM, Grayson ML, Hoy JF, eds. The Use of Antibiotics. 5th ed. Oxford, England: Butterworth-Heinemann, 1997:836-904.
7. Schmitz FJ, Verhoef J, Fluit A, et al. Stability of the MICs of various antibiotics in different, clonal populations of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1998;41:311-313.
8. The Surveillance Network Database-USA 2003. Susceptibilities of methicillin-resistant Staphylococcus aureus isolates in the United States to trimethoprim-sulfamethoxazole. Data obtained along with permission to publish from Focus Technologies, Inc, Hemdon, Virginia, USA, email: webmasterτhetsn.com.
9. Bishara J, Pitlik S, Samra Z, et al. Co-trimoxazole-sensitive, methicillin-resistant Staphylococcus aureus, Israel, 1988-1997. Emerg Infect Dis. 2003;9:1168-1169.
10. Witte W, Braulke C, Heuck D, Cuny C. Methicillin resistant Staphylococcus aureus in German hospitals develop narrower patterns of antimicrobial resistance. Euro Surveill. 2000;5:31-34.
11. Yeldandi V, Strodtman R, Lentino JR. In-vitro and in-vivo studies of trimethoprim-sulpha-methoxazole against multiple resistant Staphylococcus aureus. J Antimicrob Chemother. 1988;22: 873-880.
12. Elwell LP, Wilson HR, Knick VB, Keith BR. In-vitro and in-vivo efficacy of the combination trimethoprim-sulfamethoxazole against clinical isolates of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1986; 29:1092-1094.
13. Beam TJ. Sequestration of staphylococci at an inaccessible focus. Lancet. 1979;2:227-228.
14. Rogers D, Melly M. Speculations on the immunology of staphylococcal infections. Ann N Y Acad Sci. 1965;128:274-284.
15. Kapral F. The phagocytosis and intracellular fate of staphylococci. Ann N Y Acad Sci. 1965; 128:285-300.
16. Rogers R, Tompsett R. The survival of staphylococci within human leucocytes. Bull N Y Acad Med. 1952;28:470.
17. Gresham HD, Lowrance JH, Caver TE, et al. Survival of Staphylococcus aureus inside neutrophils contributes to infection. J Immunol. 2000;164:3713-3722.
18. Jacob R, Wilson C. Intracellular penetration and antimicrobial activity of antibiotics. J Antimicrob Chemother 1983;12(suppl C):13-20.
19. Hand WL, King-Thompson N, Holman JW. Entry of roxithromycin (RU 965), imipenem, cefotaxime, trimethoprim, and metronidazole into human polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1987;31:1553-1557.
20. de Górgolas M, Avilés P, Verdejo C, Fernandez Guerrero ML. Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis. Antimicrob Agents Chemother. 1995;39:953-957.
21. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-suffamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992;117:390-398.
22. Fridkin SK Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis. 2001;32:108-115.
23. Paradisi F, Corti G, Messeri D. Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am. 2001;85:1-17.
24. Close SJ, McBurney CR, Garvin CG, et al. Trimethoprim-sulfamethoxazole activity and pharmacodynamics against glycopeptide-intermediate Staphylococcus aureus. Pharmacotherapy. 2002;22:983-989.
25. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med. 1999;340:493-501.
26. Chambers HF. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev. 1997;10: 781-791.
27. Fung HB, Kirschenbaum HL, Ojofeitimi BO. Linezolid: an oxazolidinone antimicrobial agent. Clin Ther. 2001;23:356-391.
28. Wookey A, Turner PJ, Greenhalgh JM, et al. AZD2563, a novel oxazohdinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro. Clin Microbiol Infect. 2004;10:247-254.
29. Jorgensen JH, McElmeel ML, Trippy CW. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species. Antimicrob Agents Chemother. 1997;41: 465-467.
30. Rybak MJ, Cappelletty DM, Moldovan T, et al. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother. 1998;42:721-724.
31. Ruiz ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin Infect Dis. 2002;35:1018-1020.
32. Lamb HM, Figgitt DP, Faulds D. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs. 1999;58:1061-1097.
33. Hershberger E, Donabedian S, Konstantinou K, Zervos MJ. Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis. 2004;38:92-98.
34. Leclercq R, Nantas L, Soussy CJ, Duval J. Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics. J Antimicrob Chemother. 1992;30(suppl A):67-75.
35. Clarebout G, Nativelle E, Leclercq R. Unusual inducible cross resistance to macrolides, lincosamides, and streptogramins B by methylase production in clinical isolates of Staphylococcus aureus. Microb Drug Resist. 2001;7:317-322.